LUC00278I2 - - Google Patents
Download PDFInfo
- Publication number
- LUC00278I2 LUC00278I2 LU00278C LUC00278C LUC00278I2 LU C00278 I2 LUC00278 I2 LU C00278I2 LU 00278 C LU00278 C LU 00278C LU C00278 C LUC00278 C LU C00278C LU C00278 I2 LUC00278 I2 LU C00278I2
- Authority
- LU
- Luxembourg
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0911566.8A GB0911566D0 (en) | 2009-07-03 | 2009-07-03 | T cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LUC00278I2 true LUC00278I2 (fr) | 2025-05-12 |
Family
ID=41008692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU00278C LUC00278I2 (fr) | 2009-07-03 | 2022-09-05 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8519100B2 (fr) |
| EP (1) | EP2448963B1 (fr) |
| JP (2) | JP5872464B2 (fr) |
| CN (3) | CN107266560A (fr) |
| AU (1) | AU2010267758C1 (fr) |
| BR (1) | BR112012000107A2 (fr) |
| CA (1) | CA2766505C (fr) |
| DK (1) | DK2448963T3 (fr) |
| EA (1) | EA026918B1 (fr) |
| ES (1) | ES2498190T3 (fr) |
| FI (1) | FIC20220037I1 (fr) |
| FR (1) | FR22C1046I2 (fr) |
| GB (1) | GB0911566D0 (fr) |
| LU (1) | LUC00278I2 (fr) |
| MX (1) | MX2012000155A (fr) |
| NL (1) | NL301193I2 (fr) |
| PT (1) | PT2448963E (fr) |
| WO (1) | WO2011001152A1 (fr) |
| ZA (1) | ZA201109522B (fr) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006036445A2 (fr) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Recepteur nk chimerique et traitement anticancereux |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| WO2011059836A2 (fr) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t |
| US12492376B2 (en) | 2009-10-29 | 2025-12-09 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| WO2013048243A1 (fr) | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Molécules de liaison multispécifiques ciblant des cellules aberrantes |
| EP2802356A1 (fr) | 2012-01-13 | 2014-11-19 | Apo-T B.V. | Immunoglobulines restreintes à une cellule aberrante dotées d'une fraction toxique |
| CN104395344B (zh) | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
| WO2014036562A2 (fr) | 2012-08-31 | 2014-03-06 | University Of Virginia Patent Foundation | Peptides cibles pour l'immunothérapie et le diagnostic |
| HK1212236A1 (en) | 2012-09-05 | 2016-06-10 | University Of Virginia Patent Foundation | Target peptides for colorectal cancer therapy and diagnostics |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| PT2951202T (pt) | 2013-01-29 | 2020-07-07 | Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch | Moléculas de ligação de alta avidez que reconhecem mage-a1 |
| JP6549564B2 (ja) * | 2013-06-26 | 2019-07-24 | グアンドン シャンスエ ライフ サイエンス， リミテッド． | 高安定性のｔ細胞受容体およびその製法と使用 |
| JP6476182B2 (ja) * | 2013-11-22 | 2019-02-27 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 改変された高親和性ヒトｔ細胞受容体 |
| DE202014002754U1 (de) | 2014-03-31 | 2015-07-03 | Christian Piotrowski | Ausgusssystem mit Pullring der mit der Folie verbunden ist. |
| EP3137100B1 (fr) | 2014-04-15 | 2023-12-20 | University Of Virginia Patent Foundation | Récepteurs des lymphocytes t isolés et leurs procédés d'utilisation |
| WO2015192757A1 (fr) * | 2014-06-18 | 2015-12-23 | 广州市香雪制药股份有限公司 | Récepteur de cellules t du vhc à haute affinité |
| WO2016014725A1 (fr) * | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Constructions moléculaires et utilisations correspondantes |
| EP3177314B1 (fr) * | 2014-08-04 | 2020-10-07 | Fred Hutchinson Cancer Research Center | Immunothérapie par cellules t spécifiques de la wt-1 |
| ES2924709T3 (es) * | 2014-10-02 | 2022-10-10 | Us Health | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer |
| GB201417803D0 (en) * | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| PL3212225T3 (pl) * | 2014-10-31 | 2026-03-30 | The Trustees Of The University Of Pennsylvania | Sposoby i kompozycje zmodyfikowanych limfocytów t |
| US20190030071A1 (en) | 2014-11-03 | 2019-01-31 | IMMURES S.r.I. | T cell receptors |
| GB201506642D0 (en) * | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| AU2016273213B2 (en) * | 2015-06-01 | 2019-03-14 | Medigene Immunotherapies Gmbh | T cell receptor library |
| KR20180020202A (ko) * | 2015-06-01 | 2018-02-27 | 메디진 이뮤노테라피스 게엠바하 | T 세포 수용체 특이적 항체 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| GB201516277D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR libraries |
| EP4357454A3 (fr) | 2016-03-16 | 2024-07-24 | Immatics Biotechnologies GmbH | Lymphocytes t et récepteurs de lymphocytes t transfectes pour une utilisation en immunothérapie contre des cancers |
| HRP20221375T1 (hr) | 2016-03-16 | 2023-01-06 | Immatics Biotechnologies Gmbh | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka |
| GB201604953D0 (en) * | 2016-03-23 | 2016-05-04 | Immunocore Ltd | T cell receptors |
| BR112018069669B1 (pt) | 2016-03-28 | 2022-08-02 | Dow Global Technologies Llc | Composição adesiva sem solvente de dois componentes, método para formar um laminado e laminado |
| JP7599819B2 (ja) * | 2016-06-02 | 2024-12-16 | イムノコア リミテッド | ｇｐ１００特異的ＴＣＲ－抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン |
| DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| MY195101A (en) | 2016-08-17 | 2023-01-10 | Immatics Biotechnologies Gmbh | Novel T Cell Receptors and Immune Therapy Using the Same |
| JP2020501508A (ja) * | 2016-09-15 | 2020-01-23 | クアドルセプト バイオ リミテッド | 多量体、四量体および八量体 |
| GB201617714D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| AU2018234830B2 (en) | 2017-03-15 | 2023-03-02 | Fred Hutchinson Cancer Center | High affinity MAGE-A1-specific TCRs and uses thereof |
| DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| GB201709866D0 (en) * | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
| CN109535257B (zh) * | 2017-09-22 | 2021-05-28 | 同润生物医药(上海)有限公司 | 新型双特异性cd3/cd19多肽复合物 |
| CN117843810A (zh) | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| WO2019069125A1 (fr) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | Récepteurs d'antigènes chimériques |
| CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
| US12606816B2 (en) * | 2018-07-31 | 2026-04-21 | Janux Therapeutics, Inc. | Inhibitory T cell receptor peptides and discovery methods |
| US20210317184A1 (en) * | 2018-09-05 | 2021-10-14 | GlaxoSmithKline Intellectual Property Devolopment Limited | T cell modification |
| CN112912391B (zh) * | 2018-10-25 | 2026-07-03 | 昆士兰医学研究所理事会 | T细胞受体及其用途 |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| LT4279082T (lt) | 2019-01-17 | 2026-05-11 | Immunocore Limited | Farmacinės kompozicijos |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| GB201901306D0 (en) * | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
| US20230220105A1 (en) * | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
| KR20220052944A (ko) * | 2019-07-30 | 2022-04-28 | 유니버시티 헬스 네트워크 | Mhc 클래스 ii 분자 및 이의 사용 방법 |
| CN111234004B (zh) * | 2020-02-28 | 2023-03-28 | 陕西九州新药评价研究有限公司(西安新药评价研究中心) | 识别wt1抗原短肽的t细胞受体及其应用 |
| GB202006629D0 (en) * | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| EP4153618A4 (fr) * | 2020-05-18 | 2024-06-26 | Board of Regents, The University of Texas System | Récepteurs de lymphocytes t modifiés et leurs procédés d'utilisation |
| CN112239495B (zh) * | 2020-10-29 | 2022-04-12 | 上海药明生物技术有限公司 | 稳定的tcr结构及应用 |
| CN114853879A (zh) * | 2021-02-03 | 2022-08-05 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv的t细胞受体 |
| WO2022258606A1 (fr) | 2021-06-07 | 2022-12-15 | Gadeta B.V. | Chaînes de récepteurs de lymphocytes t delta ou de lymphocytes t gamma ou parties associées induisant une réponse antitumorale ou anti-infectieuse |
| US12103971B2 (en) | 2022-02-20 | 2024-10-01 | Immunocore Limited | HIV specific binding molecules |
| WO2023227594A1 (fr) | 2022-05-24 | 2023-11-30 | Gadeta Bv | Nouvelles chaînes de récepteurs de cellules t delta et chaînes de récepteurs de cellules t gamma ou parties de celles-ci |
| WO2023237541A1 (fr) | 2022-06-07 | 2023-12-14 | Gadeta B.V. | Chaînes de récepteurs de lymphocytes t delta ou de lymphocytes t gamma ou des parties de celles-ci qui médient une réponse anti-tumorale ou anti-infectieuse |
| WO2023246911A1 (fr) * | 2022-06-24 | 2023-12-28 | 北京可瑞生物科技有限公司 | Molécule polypeptidique bispécifique à base de récepteur de lymphocytes t et son utilisation |
| US20240075068A1 (en) | 2022-07-15 | 2024-03-07 | Gadeta B.V. | Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
| TW202423994A (zh) | 2022-08-18 | 2024-06-16 | 英商英美偌科有限公司 | 多域結合分子 |
| CA3264784A1 (fr) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Molécules de liaison à domaines multiples |
| JP2025528212A (ja) | 2022-08-18 | 2025-08-26 | イムノコア リミテッド | 複数ドメイン結合性分子 |
| CN120225664A (zh) * | 2022-09-30 | 2025-06-27 | 瑅安生物医药（杭州）有限公司 | 一种修饰细胞及其用途 |
| CN115975050A (zh) * | 2022-11-14 | 2023-04-18 | 金桥基因 | 嵌合的人源t细胞受体、核酸、载体、细胞和药物组合物 |
| EP4634216A1 (fr) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | Récepteurs de lymphocytes t se liant à des épitopes de hpv-16 |
| WO2024260454A1 (fr) * | 2023-06-21 | 2024-12-26 | 北京可瑞生物科技有限公司 | Région constante de tcr modifiée et son utilisation dans une protéine de fusion de tcr |
| GB202315181D0 (en) | 2023-10-03 | 2023-11-15 | Immunocore Ltd | Peptide-HLA binding molecules |
| WO2025087436A1 (fr) * | 2023-10-27 | 2025-05-01 | 北京可瑞生物科技有限公司 | Molécule polypeptidique multi-spécifique basée sur un récepteur de lymphocytes t, composition et utilisation associées |
| KR20260102788A (ko) | 2023-11-01 | 2026-07-01 | 이뮤노코어 리미티드 | 소형 멀티도메인 단백질의 정제 방법 |
| GB202320012D0 (en) | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| CN118108833B (zh) * | 2024-03-12 | 2025-05-02 | 缇纱(合肥)生物技术有限公司 | 引入外源二硫键的tcr恒定区及其产品和应用 |
| WO2025224692A1 (fr) | 2024-04-25 | 2025-10-30 | Immunocore Limited | Méthode de traitement du cancer à l'aide d'une signature d'expression génique |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026078231A1 (fr) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Ligand immunitaire non agrégant soluble |
| WO2026110106A1 (fr) | 2024-11-22 | 2026-05-28 | Immunocore Limited | Stabilisateur de solution intraveineuse |
| WO2026125496A1 (fr) | 2024-12-10 | 2026-06-18 | Engimmune Therapeutics Ag | Molécules multifonctionnelles comprenant des fragments de tcr solubles et leurs utilisations |
| GB202418912D0 (en) | 2024-12-20 | 2025-02-05 | Immunocore Ltd | Specific binding molecules |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688747A (en) | 1994-08-22 | 1997-11-18 | Becton Dickinson And Company | Water based lubricant solution |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| NZ507886A (en) * | 1998-05-19 | 2003-05-30 | Avidex Ltd | Multivalent T cell receptor complexes |
| PT1421115E (pt) * | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
| EP2048159B1 (fr) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | Présentation de récepteur de lymphocyte T |
| GB0227351D0 (en) * | 2002-11-22 | 2002-12-31 | Isis Innovation | Soluble T-cell receptors |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| CN101035561A (zh) * | 2004-03-24 | 2007-09-12 | 特罗斯药品公司 | 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法 |
| NZ550815A (en) | 2004-05-19 | 2009-04-30 | Immunocore Ltd | Method of improving T cell receptors |
| GB0411125D0 (en) * | 2004-05-19 | 2004-06-23 | Avidex Ltd | Method of improving T-cell receptors |
| EP1791865B1 (fr) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cellules exprimant une cellule t recepteur modifiee |
| US20060045884A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents | Vaccines for autoimmune and infectious disease |
| WO2006031221A1 (fr) * | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Préparations comprenant des récepteurs cellulaires t et méthodes d'utilisation de ces préparations |
| WO2006054096A2 (fr) * | 2004-11-18 | 2006-05-26 | Avidex Ltd | Proteines bifonctionnelles solubles |
| CN101171034B (zh) * | 2005-03-03 | 2014-06-18 | 免疫医疗公司 | 人源化l243抗体 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| EP1795599A1 (fr) * | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Procédé pour la préparation de cellules T effectrices |
| US20090304657A1 (en) | 2006-05-03 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| EP2087000A2 (fr) | 2006-09-29 | 2009-08-12 | Immunocore Ltd. | Thérapies fondées sur les lymphocytes t |
| CA2674445C (fr) | 2007-01-12 | 2016-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Recepteurs de lymphocyte t specifiques au gp100 et materiaux apparentes et procedes d'utilisation |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
-
2009
- 2009-07-03 GB GBGB0911566.8A patent/GB0911566D0/en not_active Ceased
-
2010
- 2010-07-01 EA EA201270135A patent/EA026918B1/ru not_active IP Right Cessation
- 2010-07-01 WO PCT/GB2010/001277 patent/WO2011001152A1/fr not_active Ceased
- 2010-07-01 ES ES10734524.1T patent/ES2498190T3/es active Active
- 2010-07-01 MX MX2012000155A patent/MX2012000155A/es active IP Right Grant
- 2010-07-01 PT PT107345241T patent/PT2448963E/pt unknown
- 2010-07-01 AU AU2010267758A patent/AU2010267758C1/en active Active
- 2010-07-01 BR BR112012000107A patent/BR112012000107A2/pt not_active Application Discontinuation
- 2010-07-01 CN CN201710535038.2A patent/CN107266560A/zh not_active Withdrawn
- 2010-07-01 CN CN201410257886.8A patent/CN104017067B/zh active Active
- 2010-07-01 CA CA2766505A patent/CA2766505C/fr active Active
- 2010-07-01 CN CN2010800351402A patent/CN102574906A/zh active Pending
- 2010-07-01 EP EP10734524.1A patent/EP2448963B1/fr active Active
- 2010-07-01 JP JP2012518126A patent/JP5872464B2/ja active Active
- 2010-07-01 DK DK10734524.1T patent/DK2448963T3/da active
-
2011
- 2011-12-22 ZA ZA2011/09522A patent/ZA201109522B/en unknown
-
2012
- 2012-01-03 US US13/342,579 patent/US8519100B2/en active Active
-
2013
- 2013-07-22 US US13/947,580 patent/US9068178B2/en active Active
-
2015
- 2015-10-02 JP JP2015196799A patent/JP6186412B2/ja active Active
-
2022
- 2022-08-15 NL NL301193C patent/NL301193I2/nl unknown
- 2022-08-31 FI FIC20220037C patent/FIC20220037I1/fi unknown
- 2022-09-02 FR FR22C1046C patent/FR22C1046I2/fr active Active
- 2022-09-05 LU LU00278C patent/LUC00278I2/fr unknown